CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.56B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.07: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.56BUSDvs all stocks (USD)
Trailing P/E
14.22xRevenue (TTM)
1.20BUSDvs all stocks (USD)
Profit Margin
10.14%Beta
0.9260xvs all stocks
52-Week Change
20.35%vs all stocks
Market Capitalization
1.56BUSDvs all stocks (USD)
Enterprise Value
1.78BUSDvs all stocks (USD)
Trailing P/E
14.22xForward P/E
42.24xPEG Ratio
0.1896xPrice to Sales (TTM)
1.30xPrice to Book (MRQ)
0.8485xEnterprise to Revenue
1.49xEnterprise to EBITDA
6.25xGross Margin
47.85%Profit Margin
10.14%Operating Margin
13.57%Return on Assets (TTM)
3.15%Return on Equity (TTM)
6.63%Revenue (TTM)
1.20BUSDvs all stocks (USD)
Revenue per Share (TTM)
5.14USDUpdated Jul 19, 2026Quarterly Revenue Growth
7.40%Gross Profit (TTM)
575.26MUSDvs all stocks (USD)
EBITDA (TTM)
346.95MUSDvs all stocks (USD)
Net Income (TTM)
121.24MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
85.40%Operating Cash Flow (TTM)
296.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
146.94MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
5.21MUSDFY2025 · Dec 31, 2025Revenue
1.18BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
600.40MUSDFY2025 · Dec 31, 2025Gross Profit
574.89MUSDFY2025 · Dec 31, 2025Operating Income
137.70MUSDvs all stocks (USD)
Pre-tax Income
263.36MUSDFY2025 · Dec 31, 2025Income Tax Expense
147.30MUSDFY2025 · Dec 31, 2025Net Income
116.05MUSDFY2025 · Dec 31, 2025EBIT
283.37MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
335.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
437.19MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
20.02MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.4900USDFY2025 · Dec 31, 2025EPS (Diluted)
0.4800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
233.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
233.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
116.05MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
410.36MUSDFY2025 · Dec 31, 2025Free Cash Flow
329.89MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
285.28MUSDFY2025 · Dec 31, 2025Interest Paid
21.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
116.05MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
197.01MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
144.49MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.93MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.74MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
44.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-87.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-80.47MUSDFY2025 · Dec 31, 2025Net Acquisitions
-29.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-75.66MUSDFY2025 · Dec 31, 2025Sale of Investments
167.00KUSDFY2025 · Dec 31, 2025Other Investing Activity
55.08MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-130.39MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-10.70MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-38.87MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.23MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-52.81MUSDFY2025 · Dec 31, 2025Shares Outstanding
225.93MSharesUpdated Jul 19, 2026Float Shares
190.60MSharesUpdated Jul 19, 2026% Held by Insiders
1.89%vs all stocks
% Held by Institutions
8.18%vs all stocks
Total Cash (MRQ)
344.51MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.57USDUpdated Jul 19, 2026Total Debt (MRQ)
562.37MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2964xCurrent Ratio (MRQ)
3.47xBook Value per Share (MRQ)
8.38USDUpdated Jul 19, 2026Total Assets
2.79BUSDvs all stocks (USD)
Total Current Assets
577.17MUSDFY2025 · Dec 31, 2025Total Liabilities
879.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.21BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
702.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
177.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
274.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
51.27MUSDFY2025 · Dec 31, 2025Inventory
158.29MUSDFY2025 · Dec 31, 2025Accounts Payable
24.57MUSDFY2025 · Dec 31, 2025Short-term Debt
36.85MUSDFY2025 · Dec 31, 2025Long-term Debt
481.50MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.78BUSDFY2025 · Dec 31, 2025Retained Earnings
165.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.91BUSDvs all stocks (USD)
52-Week Low
5.29USDUpdated Jul 19, 202652-Week High
10.43USDUpdated Jul 19, 202652-Week Change
20.35%vs all stocks
Beta
0.9260xvs all stocks
50-Day MA
7.65USDUpdated Jul 19, 2026200-Day MA
7.30USDUpdated Jul 19, 2026Avg 10-Day Volume
662.73KSharesUpdated Jul 19, 2026Avg 30-Day Volume
602.59KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.5000USDUpdated Jul 19, 2026Other Income / Expense
134.30MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.07: grey zoneSignificant
Altman Z-Score: 2.07
High earnings qualityNotable
Earnings Quality Score: 2.28
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.56B, above the global median of $1.15BNotable
Market cap (USD): 1,557,016,354Global Median: 1,146,734,693.424
Revenue is $1.2B, above the global median of $520.53MNotable
Revenue (USD): 1,195,944,960Global Median: 520,528,949.311
Levered free cash flow is $146.94M, above the global median of $16.24MNotable
Levered free cash flow (USD): 146,937,248Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule